Synovial Fluid Bank From Arthritic Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Université de Sherbrooke
Sponsor:
Collaborator:
Canadian Arthritis Network
Information provided by (Responsible Party):
Gilles Boire, Université de Sherbrooke
ClinicalTrials.gov Identifier:
NCT00512343
First received: August 3, 2007
Last updated: October 30, 2013
Last verified: October 2013
  Purpose

The objectives of this group project is to collect SF and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.


Condition
Arthritis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Establishment of a Bank of Synovial Fluids and Paired Sera From Arthritic Patients for the Evaluation of New Methods Facilitating the Diagnosis and the Monitoring of Progression and Therapy of Arthritis.

Further study details as provided by Université de Sherbrooke:

Primary Outcome Measures:
  • Availability of paired synovial fluid and serum samples for exploratory studies [ Time Frame: Use with various collaborators at different times, upon request and approbation ] [ Designated as safety issue: No ]
    Availability of paired synovial fluid and serum samples, linked with anonymized clinical and treatment data, from patients suffering from various arthritides (rheumatoid arthritis, gout and other microcrystalline arthritides, osteoarthritis, spondylarthropathies, juvenile idiopathic arthritis, and various other diseases, including inflammatory polyarthritis of recent-onset in adults


Biospecimen Retention:   Samples Without DNA

Synovial fluids from joints with effusion Sereum samples drawn on the same day


Estimated Enrollment: 500
Study Start Date: June 2002
Estimated Study Completion Date: September 2020
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Detailed Description:

Our group has developed interdisciplinary expertise in biomarkers related to distinct aspects of inflammation-induced joint damage, most notably those associated with degradation of components of the extracellular matrix, bone loss, or associated with post-translational changes on protease inhibitors.

The objectives of this group project is to collect SF and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.

More specifically, we will study (1) biomarkers associated with osteoclastic bone resorption and synthesis/degradation of cartilage, (2) inhibitors of enzymes (calpastatin) that are preferentially targeted by rheumatoid patients, as well as (3) enzymes (e.g. MMPs) responsible for the cleavage of components of the articular cartilage.

Finally, we propose to characterize the repertoire of specific active proteases in the SF of arthritic patients concomitantly to the use biomarkers (neoepitopes of cleaved collagens) previously associated with cartilage destruction and synthesis to identify new targets for the development of protease inhibitors for the treatment of arthritis. Furthermore, our project will also provide the opportunity to test the potential of measuring the net proteolytic activity by Fluorescent-Activated Substrate Conversion as a method of monitoring disease activity and treatment efficiency in a clinical setting.

  Eligibility

Ages Eligible for Study:   3 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients suffering from various arthritides (rheumatoid arthritis, gout and other microcristalline arthritides, osteoarthritis, spondylarthropathies, juvenile idiopathic arthritis, and various other diseases, including inflammatory polyarthritis of recent-onset in adults

Criteria

Inclusion Criteria:

  • Significant joint effusion

Exclusion Criteria:

  • Hemorrhagic effusion
  • Traumatic effusion
  • Less than 3 ml total of collected fluid (used for routine analysis and culture)
  • Inability or refusal to consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00512343

Contacts
Contact: Gilles Boire, MD, MSc (819) 564-5261 Gilles.Boire@USherbrooke.ca

Locations
Canada, Quebec
Centre hospitalier universitaire de Sherbrooke Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Gilles Boire, MD, MSc    (819) 564-5261    Gilles.Boire@USherbrooke.ca   
Principal Investigator: Gilles Boire, MD, MSc         
Sponsors and Collaborators
Gilles Boire
Canadian Arthritis Network
Investigators
Principal Investigator: Gilles Boire, MD, MSc CHUS and Université de Sherbrooke
  More Information

Publications:
Responsible Party: Gilles Boire, MD, Université de Sherbrooke
ClinicalTrials.gov Identifier: NCT00512343     History of Changes
Other Study ID Numbers: 02-12 LS, 91597
Study First Received: August 3, 2007
Last Updated: October 30, 2013
Health Authority: Canada: Ethics Review Committee

Keywords provided by Université de Sherbrooke:
Synovial Fluid
Arthritis
Paired serum/synovial fluid samples

Additional relevant MeSH terms:
Arthritis
Joint Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on July 29, 2014